A Study of LY3561774 in Participants With Mixed Dyslipidemia
Completed · Phase 2 · NCT05256654
Conditions: Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
At a glance
- Research payments reported, 2025
- $920
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 205
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3561774 (drug), Placebo (drug)
- Dates
- Started 2022-07-20; completion 2024-05-23
- Results posted
- Yes
This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.
From ClinicalTrials.gov, last updated 2025-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $920 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Preferred Primary Care Physicians Inc $920
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.